April 23rd 2024
Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3 study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
A New Standard of Care for Small Cell Lung Cancer?
December 12th 2023Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.
Read More
Mileham Evaluates Survival Outcomes of Immunotherapy in Extensive-Stage SCLC
November 16th 2023During a Community Case Forum event in partnership with the South Carolina Oncology Society, Kathryn Mileham, MD, discussed the significance of the IMpower133 and CASPIAN trials for patients with extensive-stage small cell lung cancer.
Read More
Physicians Compare Platinum Rechallenge With Other Second-Line Options in ES-SCLC
September 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed with participants how they would treat a patient with small cell lung cancer after prior treatment with carboplatin plus etoposide.
Read More
Leal Reviews State of Second-Line Therapy Options for ES-SCLC
July 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed treatment options for recurrent extensive-stage small cell lung cancer, including topotecan, lurbinectedin, and platinum rechallenge.
Read More
Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC
June 2nd 2023Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research
Read More